Dr Juruena is Clinical Senior Lecturer in Translational Psychiatry at the Centre for Affective Disorders and Consultant Psychiatrist at the National Affective Disorders Service, he is the lead consultant of the Maudsley Advance Treatment Service (MATS) and Maudsley Hospital ECT Service.
Area of expertise
Currently, Dr Juruena is the Lead Consultant Psychiatrist of the Maudsley Advanced Treatment Service (MATS) providing specialist assessment and advanced treatment for resistant affective disorders, including treatment-resistant depression (TRD) and treatment-resistant bipolar disorder (TRBD). The MATS include evaluation, treatment recommendation and advanced treatments, such as electroconvulsive therapy (ECT), vagus nerve stimulation therapy (VNS), ketamine, esketamine complex and/or novel pharmacotherapy (including Virtual Lithium Clinic).
Dr Juruena has been developing continuous education across community teams. Ongoing research for new treatments and guidance that can support Trust patients and clinicians in the management of resistant and difficult to treat patients affective patients.
The primary focus of Dr Juruena research is diagnostic, psychopharmacology, psychoneuroendocrinology and clinical trials in affective disorders looking to understand the aetiology, neurobiology and long-term outcome of treatment-resistant depression (TRD), resistant bipolar (TRB) and relation to comorbidities. Running this programme, he has been studying the connections between stress, mainly early life stress by neuroendocrine axis and with a particular history of childhood trauma and cognition and clinical trials in psychopharmacotherapy.
His group has been interested in developing biomarkers, particularly neuroendocrine biomarkers. For the first time, Dr Juruena and his team analysed the extent to which mineralocorticoid receptors (MR) contribute to HPA axis suppression in treatment-resistant depressed (TRD) patients. Additionally, he was able to link the MR function prospectively at the baseline to the long-term therapeutic response to the antidepressant treatment in a prospective component of the study in TRD patients.
It has become more significant with the developing of a new suppressive test for the HPA axis using prednisolone (Juruena et al. 2006, 2007, 2009, 2010, 2013, 2014, 2015, 2018). Additionally, his studies found a marked hypercortisolism in TRD sufficiently severe to require inpatient treatment and was able to link the MR function prospectively at the baseline to the long-term therapeutic response to the antidepressant treatment in a prospective component of the study in TRD patients.
In 2016, he had returned to the UK after obtaining a prestigious Fellowship from both the Royal Society and the Academy of Medical Sciences, developing the project MR assessment in bipolar depression (BD) with early life stress (ELS), in this study, was assessed the relationship of two different stress hormones cortisol and aldosterone, in patients with bipolar depression with or without a history of early life stress. Dr Juruena et al. have demonstrated for the first time that MR polymorphisms influence aldosterone and cortisol levels, indicating the crucial role of MR receptor function within the BD more susceptible to aldosterone changes when exposed to ELS.
Dr Juruena is Senior Clinical Lecturer in Translational Psychiatry and Consultant Psychiatrist at the Trust, currently the lead consultant for the Maudsley Advanced Treatment Service (MATS) for Recurrent and Treatment-Resistant Depression and Bipolar and the Maudsley Hospital ECT Service at the Trust. Several years of experience in conducting outpatient and outreach clinics have refined his consultation skills to ensure patient satisfaction while recognising the importance of running his clinics to time.
Dr Juruena has published over 100 original research articles, reviews and book chapters, and edited five books. Most of his studies are related to the neurobiology, diagnosis and treatment of affective disorders; and their relationship to stress.
The British Association awarded him for Psychopharmacology ‘The Senior Clinical Psychopharmacology Award’. Also, He received the Robert W. Kerwin Psychopharmacology Prize from the Royal College of Psychiatrists for the best article published on the subject in the British Journal of Psychiatry. More recently, he was awarded the Newton Fellow from Royal Society and Academy of Medical Sciences.
Education and Training
Dr Juruena graduated in Medicine from Pontifical Catholic University, Southern Brazil. He completed his Psychiatry Training at the Porto Alegre Mental Health School and received his MPhil at the Federal University of Sao Paulo and then MSc Affective Neuroscience, at Maastricht University in the Netherlands. Dr Juruena received his PhD in Psychiatry at the University of London/King’s College London. Mario has also completed Specialisation in Cognitive Psychotherapy at Beck Institute, Philadelphia, USA.
- Postdoctoral Clinical Fellow Royal Society/Academy of Medical Sciences, King’s College London, Psychiatry, 2016
- Postdoctoral Clinical Fellow Department of Neurosciences and Behaviour - University of Sao Paulo, Psychiatry, 2009
- Full Specialist Registration General Medical Council (GMC), UK General Adult Psychiatry, 2008
- PhD University of London - King’s College London, Psychiatry, 2007
- MSc in Affective Neuroscience Universiteit Maastricht in the Netherlands, Affective Neuroscience, 2004
- CCST in Psychiatry The Specialist Training Authority of the Medical Royal Colleges, UK General Adult Psychiatry, 2003
- Specialist in CBT Beck Institute for Cognitive Therapy and Research - Philadelphia, USA, CBT, 1999
- MPhil in Psychobiology Department of Psychobiology, Federal University of Sao Paulo, Psychopharmacology, 1995
- SpR (ST in Psychiatry) Department of Psychiatry - Federal University of Sao Paulo/Saint Paul Hospital, General Adult Psychiatry, 1994
- SHO (CT in Psychiatry) Saint Peter Psychiatric State Hospital - Porto Alegre, Psychiatry and Mental Health, 1991
- SHO (CT in GP) School of Public Health, Murialdo School Health, Brazil, General Practitioner in Medicine, 1989
- MD Pontifical Catholic University - Porto Alegre, Faculty of Medicine, Medicine, 1987
Dr Juruena published over 100 original research articles, reviews and book chapters, and edited five books. The vast majority of his studies are related to the neurobiology, diagnostic, pathophysiology, and therapeutics of Mood Disorders (Depression and Bipolar) - including TRD, Treatment-Resistant Bipolar, Psychopharmacology (antidepressants, mood stabilizers, atypical antipsychotics, new drugs, clinical trials) Neuromodulation, Psychoneuroendocrinology (HPA axis, Stress) Early Life Stress and their approach to Mental Health. Dr Juruena has approximately 600 abstracts published in more than 900 meetings presentations. h-Index=33, >3830 citations, >2470 citations from 2015-May 2020.
Juruena MF, Young AH, Hodsoll J, Lewis G, Veale D. Efficacy and Safety of Bright Light Therapy for Bipolar Depression
. Psychiatry Clin Neurosci. 2020 Apr 5. doi: 10.1111/pcn.13005
Figaro-Drumond FV, Pereira SC, Menezes IC, von Werne Baes C, Coeli-Lacchini FB, Oliveira-Paula GH, Cleare AJ, Young AH, Tanus-Santos JE, Juruena MF, Lacchini R. Association of 11β-hydroxysteroid dehydrogenase type1 (HSD11b1) gene polymorphisms with outcome of antidepressant therapy and suicide attempts.
Behav Brain Res. 2020 Mar 2;381:112343.
Juruena MF, Eror F, Cleare AJ, Young AH. The Role of Early Life Stress in HPA Axis and Anxiety.
Adv Exp Med Biol. 2020;1191:141-53.
Mendes-Ribeiro J., Juruena M., Caropreso L., Eltayebani M.M., Streiner D.L. (2020) Psychometric Instruments and Women’s Mental Health
. In: Rennó Jr. J., Valadares G., Cantilino A., Mendes-Ribeiro J., Rocha R., Geraldo da Silva A. (eds) Women's Mental Health. Springer, Cham. 31-47.
Soda T, McLoughlin DM, Clark SR, Oltedal L, Kessler U, Haavik J, Bousman C, Smith DJ, Bioque M, Clements CC, Loo C, Vila-Rodriguez F, Minelli A, Mickey BJ, Milev R, Docherty AR, Langan Martin J, Achtyes ED, Arolt V, Redlich R, Dannlowski U, Cardoner N, Clare E, Craddock N, Di Florio A, Dmitrzak-Weglarz M, Forty L, Gordon-Smith K, Husain M, Ingram WM, Jones L, Jones I, Juruena M, Kirov G, Landén M, Müller DJ, Nordensköld A, Pålsson E, Paul M, Permoda A, Pliszka B, Rea J, Schubert KO, Sonnen JA, Soria V, Stageman W, Takamiya A, Urretavizacaya M, Watson S, Zavorotny M, Young AH, Vieta E, Rybakowski JK, Gennarelli M, Zandi PP, Sullivan PF, Baune BT. International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic).
Eur Arch Psychiatry Clin Neurosci. 2019 Dec 4.
Agustini B, Bocharova M, Walker AJ, Berk M, Young AH, Juruena MF. Has the sun set for seasonal affective disorder and HPA axis studies? A systematic review and future prospects.
J Affect Disord. 2019 Sep 1;256: 584-93.
Macedo BBD, von Werne Baes C, Menezes IC, Juruena MF. Child Abuse and Neglect as Risk Factors for Comorbidity Between Depression and Chronic Pain in Adulthood.
J Nerv Ment Dis. 2019 Jul;207(7):538-45.
Mazer AK, Cleare AJ, Young AH, Juruena MF. Bipolar affective disorder and borderline personality disorder: differentiation based on the history of early life stress and psychoneuroendocrine measures.
Behavioural Brain Research Jan 2019, 357, 48-56.
Menezes IC, Baes CV, Lacchini R, Juruena MF. Genetic biomarkers for differential diagnosis of major depressive disorder and bipolar disorder: a critical and systematic review.
Behavioural Brain Research, Jan 2019, 357,29-38.
Martins-Monteverde CMS, Baes CVW, Reisdorfer E, Padovan T, Tofoli SMC, Juruena MF. Relationship Between Depression and Subtypes of Early Life Stress in Adult Psychiatric Patients.
Front Psychiatry. 2019 5;10:19.
Delia ATD, Matsuzaka CT, Neto JBB, Mello MF, Juruena MF Mello AF. Childhood sexual abuse and indicators of immune activity: a systematic review.
Frontiers in Psychiatry 9,354, Aug 2018.
Juruena MF, Bocharova M, Agustini B, Young AH. Atypical and Non-Atypical Depression: Is HPA Axis Function a Biomarker?
Journal of Affective Disorders, Jun 2018;233: 45-67.
Juruena MF, Cleare A, Young A. (2018). The Role of Early Life Stress in HPA Axis and Depression.
Understanding Depression 71-80.
Ferreira Mattos P, Mozzambani A, Pedrini J, Fiks J, Juruena M, Feijo de Mello M. (2018). Peritraumatic Dissociation and PTSD: a Shortcut to Neurodegeneration?.
Neuropsychiatry, (03), doi: 10.4172/Neuropsychiatry.1000424
Borges VF, Juruena MF, Mendes N, Estanislau CR. Recognition of a response to potential threat: evidence for a facial expression of anxiety?
Psychology and Neuroscience APA journal, 11(1) 2018.
Bosaipo NB, Foss MP, Young AH, Juruena MF. Neuropsychological Changes in Melancholic and Atypical Depression.
Neuroscience & Biobehavioural Reviews. 2017;73: 309-25.
Juruena MF, Agustini B, Cleare AJ, Young AH. A translational approach to clinical practice via stress-responsive glucocorticoid receptor signalling.
Stem cell investigation. 2017;(16) 4: 13.
Hidalgo-Mazzei D, Reinares M, Mateu A, Juruena MF, Young AH, Pérez-Sola V, ... Colom F. (2017). Is a SIMPLe smartphone application capable of improving biological rhythms in bipolar disorder?
. Journal of affective disorders, 223, pp. 10-16
Weber CA, Juruena MF. (2016). Day hospital and psychosocial care center: Expanding the discussion of partial hospitalization in mental health.
Rev. Assoc. Med. Bras., (1992), 62(4), pp. 361-7.
Mello AF, Juruena MF, et al. Factors related to the cortisol awakening response of children working on the streets and siblings, before and after two years of a psychosocial intervention.
Psychiatry Research. 2015; 225(3): 625–30.
Juruena MF, Baes CV, Menezes IC, Graeff, FG. Early Life Stress in Depressive Patients: Role of Glucocorticoid and Mineralocorticoid Receptors and of Hypothalamic-Pituitary-Adrenal Axis Activity.
Current Pharmaceutical Design. 2015; 21(11): 1369-78.
Mello AF, Juruena MF, Maciel MR, Cavalcante-Nobrega LP, Cividanes GC, Fossaluza V, Calsavara V, Mello MF, Cleare AJ, Mari J de J Factors related to the cortisol awakening response of children working on the streets and siblings, before and after 2 years of a psychosocial intervention.
Psychiatry Res. 2015 Feb 28;225(3):625-30
Martins CM, Von Werne Baes C, Tofoli SM, Juruena MF. Emotional abuse in childhood is a differential factor for the development of depression in adults.
J Nerv Ment Dis. 2014 Nov;202(11):774-82.
Wooderson S, Fekadu A, Markopoulou K, Rane LJ, Poon L, Juruena MF, Strawbridge R, Cleare AJ. Long-term symptomatic and functional outcome following an intensive inpatient multidisciplinary intervention for TR affective disorders.
Journal of Affective Disorders. 2014; 166:334-42.
Baes CV, Martins CM, Tofoli SM, Juruena MF. Early life stress in depressive patients: HPA axis response to GR and MR agonist.
Frontiers in Psychiatry. 2014; 5(2).
Tunnard C, Rane LJ, Wooderson SC, Markopoulou K, Poon L, Fekadu A, Juruena MF, Cleare AJ. The impact of childhood adversity on suicidality and clinical course in treatment-resistant depression.
Journal of Affective Disorders. 2014; 152: 122-30.
Juruena MF. Early-life stress and HPA axis trigger recurrent adulthood depression.
Epilepsy & Behaviour. 2014; 38: 148-59.
Carr CP, Martins CM, Stingel AM, Lemgruber VB, Juruena MF. The role of early life stress in adult psychiatric disorders: a systematic review according to childhood trauma subtypes.
The Journal of nervous and mental disease. 2013; 201(12): 1007-20.
Tursi MF, Baes Cv, Camacho FR, Tofoli SM, Juruena MF. Effectiveness of psychoeducation for depression: a systematic review.
Tursi MF, Baes Cv, Camacho FR, Tofoli SM, Juruena MF. Aust N Z J Psychiatry. 2013 Nov;47(11):1019-31
de Jesus Mari J, Tófoli LF, Noto C, Li LM, Diehl A, Claudino AM, Juruena MF. Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies.
Drugs. 2013 Sep;73(14):1549-68
Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ. The role of mineralocorticoid receptor function in treatment-resistant depression.
Journal of Psychopharmacology (Oxford). 2013; 27(12): 1169-79.
Moreira L, Bins HT, Ferro C, Harttmann T, Petribu K, Juruena MF, Do Rosario MC, Ferrao YA. An exploratory dimensional approach to premenstrual manifestation of obsessive-compulsive disorder symptoms: A multicentre study.
Journal of Psychosomatic Research. 2013; 74: 313-19.
Carvalho LA, Torre JP, Papadopoulos AS, Poon L, Juruena MF, Markopoulou K, Cleare AJ, Pariante CM. Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system.
Journal of Affective Disorders. 2013; 148: 136-40.
Valiengo LL, Soeiro-de-Souza, MG, Andreazza AC, Juruena MF, Gattaz WF, Moreno DH, Marques AH, Machado-Vieira R. Plasma cortisol in first episode drug-naïve mania: Differential levels in euphoric versus irritable mood.
Journal of Affective Disorders. 2012; 138: 149-52.
Baes CV, Tofoli SM, Martins CM, Juruena MF. Assessment of the hypothalamic-pituitary-adrenal axis activity: glucocorticoid receptor and mineralocorticoid receptor function in depression with early life stress - a systematic review.
Acta Neuropsychiatrica. 2012; 24: 4-15.
Khairova R, PA war R, Salvadoran G, Juruena MF, De Sousa RT, Soeiro-de-Souza MG, Salvador M, Zarate CA, Gattaz WF, Machado-Vieira, R. Effects of lithium on oxidative stress parameters in healthy subjects.
Molecular Medicine Reports. 2012; 5: 680-82.
Von Werne Baes C, de Carvalho Tofoli SM, Martins CM, Juruena MF. Assessment of the hypothalamic-pituitary-adrenal axis activity: glucocorticoid receptor and mineralocorticoid receptor function in depression with early life stress - a systematic review.
Acta Neuropsychiatr. 2012 Feb;24(1):4-15
Juruena MF. Understanding subthreshold depression.
Shanghai Arch of Psychiatry. 2012;24: 292-93.
Wooderson SC, Juruena MF, Fekadu A, Commane C, Donaldson C, Cowan M, Tomlinson M, Poon L, Markopoulou K, Rane L, Donocik J, Tunnard C, Masterson B, Cleare AJ. Prospective evaluation of specialist inpatient treatment for refractory affective disorders.
J Affect Disord. 2011 Jun;131(1-3):92-103.
Juruena MF, Sena EP, De Oliveira IR. Sertindole in the Management of Schizophrenia. Journal of Central Nervous System Disease.
Juruena MF, Calil HM, Fleck MP, Del Porto JA. Melancholia in Latin American studies: a distinct mood disorder for the ICD-11.
Braz J Psychiatry. 2011; 33: S37-S58.
Juruena MF, De Sena EP, De Oliveira I. Specific mechanism of action of amisulpride in the treatment of schizophrenia and correlation with clinical response and tolerability.
Journal of Receptor, Ligand and Channel Research. 2011; 4: 49-55.
Juruena MF. An integrative science approach: neuroscience in the DSM-5 and ICD-11.
Acta Neuropsychiatrica. 2011; 23: 143-44.
Doring TM, Kubo TT, Cruz LC Jr, Juruena MF, Fainberg J, Domingues RC, Gasparetto EL Evaluation of hippocampal volume based on MR imaging in patients with bipolar affective disorder applying manual and automatic segmentation techniques.
J Magn Reson Imaging. 2011 Mar;33(3):565-72.
Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM. The prednisolone suppression test in depression: dose-response and changes with antidepressant treatment.
Psychoneuroendocrinology. 2010 Nov;35(10):1486-91.
Juruena MF, Giampietro VP, Smith SD, Surguladze SA, Dalton JA, Benson PJ, Cleare AJ, Fu CH Amygdala activation to masked happy facial expressions.
J Int Neuropsychol Soc. 2010 Mar;16(2):383-7
Juruena MF, de Sena EP, de Oliveira IR. Safety and tolerability of antipsychotics: focus on Amisulpride. Drug, Healthcare and Patient Safety.
Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ. Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance.
British Journal of Psychiatry. 2009;194: 342-49.
Fleck MP, Berlim MT, Lafer B, Sougey EB, Del Porto JA, Brasil MA, Juruena MF, Hetem LA. Review of the guidelines of the Brazilian Medical Association for the treatment of depression (Full version)
. Braz J Psychiatry. 2009; 31: S7-S17.
Juruena MF, Gama CS, Berk M, Belmonte-de-Abreu PS. Improved residual symptoms in bipolar affective disorder with adjunctive spironolactone (mineralocorticoid receptor antagonist): Case series.
Journal of Psychopharmacology (Oxford), 2009; 23(8): 985-87.
Markopoulou K, Papadopoulos AS, Juruena MF, Poon L, Pariante CM, Cleare AJ. The ratio of cortisol/DHEA in treatment resistant depression.
Psychoneuroendocrinology. 2009; 34: 19-26.
Juruena MF, Ottoni G, Machado-Vieira R, Carneiro R, Weingarthner N, Fleig SS, Broilo L, Busnello ED. Bipolar I and II disorder residual symptoms: Oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2009; 33: 94-9.
Carvalho LA, Juruena MF, Papadopoulos AS, Poon L, Kerwin R, Cleare AJ, Pariante CM. Clomipramine In Vitro Reduces Glucocorticoid Receptor Function in Healthy Subjects but not in Patients with Major Depression.
Neuropsychopharmacology. 2008; 33: 3182-89.
Mello A, Juruena MF, Pariante CM, Tyrka AR, Price LH, Carpenter LL, Del Porto JA. Depression and stress: is there an endophenotype.
Braz J Psychiatry. 2007; 29: 13-8.
Juruena MF, Marques AH, Mello A, Mello M. A Paradigm for understanding and treating psychiatric illness.
Braz J Psychiatry, 2007;29: 1-2.
Juruena MF, Cleare AJ. Overlap between atypical depression, seasonal affective disorder and chronic fatigue syndrome
Braz J Psychiatry 2007; 29: 20-7.
Juruena MF. The neurobiology of TRD: role of the HPA axis and GR and MR function. Supervisors: AJ Cleare and CM Pariante.
PhD thesis University of London Kings College London, 2007.
Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM. Different responses to dexamethasone and prednisolone in the same depressed patients.
Psychopharmacology. 2006; 189(2): 225-35.
De Oliveira IR, Juruena MF. Treatment of psychosis: 30 years of progress.
Journal of Clinical Pharmacy and Therapeutics. 2006; 31(6): 523-34.
Juruena MF. Prednisolone Effective as Test for Hormone Imbalance in Patients with Treatment-Resistant.
Primary Psychiatry. 2006; 13: 15-6.
Juruena MF. Bipolar II vs. Bipolar I: more differences than previously thought.
Dissertation presented towards a Masters’ Degree in Affective Neuroscience (MSc) by the University of Maastricht, NL. Supervisor: C Faravelli, 2004.
Spanemberg L, Juruena MF. Dysthymia: nosological characteristics and its relationship with major depressive disorder.
Trends in Psychiatry and Psychotherapy. 2004; 26(3): 300-11.
Juruena MF, Cleare AJ, Pariante CM. Hypothalamic Pituitary Adrenal axis, Glucocorticoid receptor function and relevance to depression.
Braz J Psychiatry. 2004; 26(3): 189-201.
Fleck M, Lafer B, Sougey E, Del Porto JA, Brasil MA, Juruena MF. Guidelines of Brazilian Medical Association for the treatment of depression
Braz J Psychiatry. 2003; 25(2): 114-22.
Juruena MF, Cleare AJ, Bauer ME, Pariante CM. Molecular mechanism of GR sensitivity and relevance for affective disorders.
Acta Neuropsychiatrica. 2003;15: 354-67.
Do Prado Lima P, Knijnik L, Juruena MF, Padilla A. Lithium reduces maternal child abuse behaviour: a preliminary report.
Journal of Clinical Pharmacy and Therapeutics. 2001; 26: 279-82.
Juruena MF. Cognitive therapy for Bipolar Disorder.
Archives of Clinical Psychiatry; 2001. 28, 322-30.
Tavares R, Juruena MF. Double depression: an example of recurrent affective disorder.
Archives of Clinical Psychiatry. 2001; 28(3): 114-19.
Gentil V, Kerr-Correa F, Moreno R, Busnello E, Campos J, Juruena MF, Lafer B, Moreno D, Rosa L, Tiosso A, Benedictis E. Double-Blind Comparison of Venlafaxine and Amitriptyline in Outpatients with Major Depression with or without Melancholia.
Journal of Psychopharmacology. 2000; 14: 61-6.
Calil H, Hachul D, Juruena MF, Crespin J, Pires M. Evaluation of seasonal changes in mood and behaviour in Sao Paulo Brazil.
Acta Psiquiatrica Psicologica da America Latina. 2000; 46(2): 109-18.
Busnello E, Tannous A, Gigante L, Ballester D, Hidalgo M, Silva V, Juruena MF, Dalmolin A, Baldisserotto G. Diagnostic Reliability of Mental Disorders of the International Classification of Diseases – Primary Care.
Journal of Public Health. 1999; 33(5): 487-94.
Manica AL, Leaes CG, Frey BN, Juruena MF. The Role of Depression in Coronary Artery Disease.
Brazilian Archives of Cardiology. 1999; 73(2).
Picon P, Kapczinski F, Fichbein B, Ballester D, Gauer G, Juruena MF, Pereira M, Silveira R, Fijtmann R. Cognitive-behavioural therapy and pharmacotherapy of social phobia.
Trends in Psychiatry and Psychotherapy. 1999;21(1): 52-65.
Bonamigo DR, Juruena MF. The impact of Depression in Coronary Artery Disease.
Pesquisa Médica. 1998;32(2): 14-8.
Juruena MF, Pires ML, Calil HM. Moclobemide Effects on Prolactin Plasma Levels in Healthy Individuals: The Hormonal Increase Induced by a Single Dose is Maintained During a 4- Week Period of Drug Intake.
International Clinical Psychopharmacology. 1997; 12: 317-21.
Gauer G, Luz C, Bauer M, Juruena MF, Menezes R, Oliveira G, Gauer R, Luz C, Silveira R, Pazzato L, Rodriguez Neto K, Preger J, Oliveira M, Baptista W. Clinical relation between Major depression and Immune system activity.
Trends in Psychiatry and Psychotherapy. 1995; 17(1): 68-70.
Juruena MF. Moclobemide Effects on Prolactin Plasma Levels in Healthy Individuals: 4 - Week Period of Drug Intake; MAO platelet and Polysomnography effects.
Supervisor: HM Calil – MPhil Thesis, Federal University of Sao Paulo, 1994.